ArticleDiscover oncology2025
Uncovering GSTK1 and PTGER3 as biomarkers for breast cancer prognosis through comprehensive analyses.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Identification and validation of a seven-gene metastasis-associated prognostic model in breast cancer.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer threatens women’s health globally, and identifying prognostic genes is therefore critical for optimizing diagnosis and therapy. In this study, we retrieved datasets from the GEO database, and differential analysis subsequently identified 66 DEGs. GO and KEGG enrichment analyses revealed these DEGs were not only enriched in biological processes like angiogenesis and granulocyte differentiation but also in key pathways including Th17 cell differentiation and cancer transcriptional dysregulation. Subsequently, we evaluated 21 machine learning algorithms, among which RidgeCV and XGBoost significantly outperformed others. Specifically, prognostic models constructed based on these two algorithms exhibited excellent performance in decision curve analysis, confusion matrix evaluation, and feature importance assessment. Consequently, Cox regression analysis of the 29 overlapping genes identified by both models pinpointed GSTK1 and PTGER3 as key prognostic genes. Notably, GSTK1 and PTGER3 were underexpressed in breast cancer tissues, with high diagnostic potential and a strong correlation with pathological staging. Moreover, high expression of these two genes correlated with favorable patient survival, and a nomogram integrating them could effectively predict patient survival probabilities. Additionally, CIBERSORT and ssGSEA analyses linked GSTK1/PTGER3 to immune cell infiltration in the tumor microenvironment, further indicating their crucial roles in regulating the breast cancer immune landscape. In vitro experiments further confirmed that GSTK1 and PTGER3 are weakly expressed in breast cancer cells, and their high expression could inhibit the proliferation of breast cancer cells while predicting favorable patient survival outcomes. Collectively, this study identifies GSTK1 and PTGER3 as potential biomarkers for breast cancer precision medicine, thereby providing valuable insights into disease pathogenesis and novel therapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.